In the aftermath of the anthrax attacks of 2001, the swine flu pandemic of 2009, the Ebola outbreak of 2014, and the recent Zika scare, biodefense is more important than ever. It's no surprise that governments across the globe consistently place it at or near the top of their national-security agendas. In the U.S., one of the major players in this area is Emergent BioSolutions (NYSE:EBS).
Business Overview
Founded in 1998, Emergent develops, manufactures, and sells medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company's revenue is divided into three components: product sales (~63% of revenue), contracts and grant awards (~26%), and contract manufacturing (~12%). This report will mainly focus on the first two components as these represent Emergent's core business.
